ArticleInternational journal of molecular medicine2017
MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma.
Article in International journal of molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Interleukin-2 enhancer binding factor 2 negatively regulates the replication of duck hepatitis A virus type 1 by disrupting the RNA-dependent RNA polymerase activity of 3D polymerase.Veterinary research · 2024Article
- ILF2: a multifaceted regulator in malignant tumors and its prospects as a biomarker and therapeutic target.Frontiers in oncology · 2024Review
- Role of MicroRNA-7 (MiR-7) in Cancer Physiopathology.International journal of molecular sciences · 2022Review
- Serine hydroxymethyltransferase 2 (SHMT2) potentiates the aggressive process of oral squamous cell carcinoma by binding to interleukin enhancer-binding factor 2 (ILF2).Bioengineered · 2022Article
- ZNF488 Promotes the Invasion and Migration of Pancreatic Carcinoma Cells through the Akt/mTOR Pathway.Computational and mathematical methods in medicine · 2022Article
- Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.Frontiers in pharmacology · 2022Review
- Review
- Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma.Clinical and translational medicine · 2021Article
- MiR-7 in Cancer Development.Biomedicines · 2021Review
- Detection of genes responsible for cetuximab sensitization in colorectal cancer cells using CRISPR-Cas9.Bioscience reports · 2020Article
- Role of microRNA-7 in liver diseases: a comprehensive review of the mechanisms and therapeutic applications.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020Review
- Analysis and Identification of Tumorigenic Targets of MicroRNA in Cancer Cells by Photoreactive Chemical Probes.International journal of molecular sciences · 2020Article
- Blocking circ_0013912 Suppressed Cell Growth, Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells in vitro and in vivo Partially Through Sponging miR-7-5p.Cancer management and research · 2020Article
- The Protective Effect of Polyphenols for Colorectal Cancer.Frontiers in immunology · 2020Review
- HOXA-AS2 promotes type I endometrial carcinoma via miRNA-302c-3p-mediated regulation of ZFX.Cancer cell international · 2020Article
- Article
- ILF2 cooperates with E2F1 to maintain mitochondrial homeostasis and promote small cell lung cancer progression.Cancer biology & medicine · 2019Article
- miR-7-5p inhibits cell migration and invasion in glioblastoma through targeting SATB1.Oncology letters · 2019Article
- miR-7 Suppresses Tumor Progression by Directly Targeting MAP3K9 in Pancreatic Cancer.Molecular therapy. Nucleic acids · 2018Article
- Article
Corrections and comments
- Retraction · 2025-05-05Concerns/Issues about Data · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Plagiarism of Data · · See also: https://pubpeer.com/publications/091A39A0129F38F6A09115D04F3D0F
- Retracted
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin enhancer binding factor 2 (ILF2) has been found to be markedly upregulated in pancreatic carcinoma and is involved in the pathogenesis of pancreatic carcinoma. Thus, ILF2 may be a potential target for therapy. Yet, the regulatory mechanisms of ILF2 in pancreatic carcinoma remain largely elusive. In the present study, we demonstrated that ILF2 functioned as an oncogene and regulated epithelial-mesenchymal transition (EMT)-associated genes in pancreatic carcinoma PANC-1 cells. MicroRNA-7 (miR-7) suppressed ILF2 mRNA expression and the protein level in PANC-1 cells. Contrary to ILF2, miRNA-7 functioned as a tumor-suppressor gene and negatively regulated EMT-associated genes in the PANC-1 cells. Curcumin, a polyphenol natural product isolated from the rhizome of the plant Curcuma longa, has emerged as a promising anticancer therapeutic agent. We found that treatment with curcumin increased miR-7 expression and suppressed ILF2 protein in the PANC-1 cells. Thus, we identified ILF2 as a new downstream target gene of curcumin. The results revealed that ILF2 is regulated by miR-7 and suggest that downregulation of miR-7 may be an important factor for the ILF2 overexpression in pancreatic carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.